Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01187303

Enrollment

Registered

2010-08-24

Start date

2011-05-31

Completion date

2015-09-30

Last updated

2015-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed NLPHL

Brief summary

The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

Interventions

DRUGOfatumumab

300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* relapsed nodular lymphocyte predominant hodgkin lymphoma * age 18 - 75 * review of diagnosis by experienced pathologist * no major organ dysfunction

Exclusion criteria

* classical hodgkin lymphoma * CD20 antibody treatment within the last 6 months prior enrollment * chronic or current infectious disease requirering systemic antibiotics * other past or current malignancy

Design outcomes

Primary

Measure	Time frame
Overall response rate	12 months after end of treatment

Secondary

Measure	Time frame
duration of response	12 months after end of treatment
Progression free survival	12 months after end of treatment
adverse events	12 months after end of treatment

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026